Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Other solid neoplasm 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1

Interventions

Cisplatin 47pembrolizumab 37Magnetic Resonance Spectroscopy 33Specimen Handling 27Radiotherapy, Intensity-Modulated 21Cetuximab 19Nivolumab 18Carboplatin 16Platinum 151,2-diaminocyclohexaneplatinum II citrate 15Radiotherapy 14Biopsy 12Paclitaxel 11Gemcitabine 10Docetaxel 10Surveys and Questionnaires 9Radiation 9Immunoglobulin G 7Disulfides 7toripalimab 6cemiplimab 6Ipilimumab 6Fluorouracil 6Bevacizumab 6dostarlimab 5atezolizumab 5Watchful Waiting 5Taxes 5Immune Checkpoint Inhibitors 5Drug Therapy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
berzosertib × Head & Neck × 30 days × Clear all
NCT02567422 2026-06-02

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
43 enrolled 16 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡